ADDvise Group publishes bond prospectus and applies for listing of its bonds on Nasdaq Stockholm

10-03-2023   Regulatory press release

ADDvise Group AB (publ) (the "Company") issued on 16 December 2022 a senior secured bond loan of SEK 150,000,000 within a total framework amount of SEK 650,000,000 on the Swedish bond market. The bonds carry a floating rate interest of STIBOR 3m + 7.25 per cent per annum and matures May 21, 2024.

The Company has applied for listing of the bonds on the corporate bond list at Nasdaq Stockholm. The bonds will be admitted to trading on or about March 14, 2023.

In connection with this the Company has prepared a prospectus. The prospectus has been approved by the Swedish Financial Supervisory Authority. The Prospectus will be available on the Financial Supervisory Authority's website (www.fi.se) and on the Company's website (www.addvisegroup.com).
 

For additional information, please contact:

Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Hanna Myhrman, General Counsel
+46 709-82 92 23
hanna.myhrman@addvisegroup.se
 

About ADDvise Group
 

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group’s shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.

 

Latest press releases

Year-end report 2022, January 1-December 31

Regulatory

October–December 2022 Net revenue for the period was SEK 320.3 million (155.0), an increase of 106.6 %. Organic growth was 5.5 %. Orders received for the period was SEK 517.7 million (177.6), an increase of 191.5 %. Organic growth was 7.7 %. Adjusted EBITDA for the period was SEK 85.8 million (19.0) EBITDA for the…

ADDvise presents financial targets for 2023

Regulatory

The Board of Directors of ADDvise Group has adopted financial targets for the financial year 2023: -          Net sales pro forma rolling 12 months shall by the end of the year reach SEK 1.6 billion. -          EBITDA pro forma rolling 12 months shall by the end of the year reach SEK 330 million. The below…

ADDvise signs Letter of Intent to acquire Diabetic Supplies Inc.

Regulatory

ADDvise Group has signed a Letter of Intent with the shareholder of Diabetic Supplies Inc. (”Diabetic Supplies” or the “Company”) regarding an acquisition of all shares in Diabetic Supplies. Diabetic Supplies is based in Columbus, Ohio, USA and is a distributor of medical devices for diabetic patients. The Company distributes, among other things, continuous glucose…